‘Fatty retina’: A root cause of vision loss in diabetes?
Vision loss in diabetes, one of the most feared complications of this disease, is caused by a progressive pathogenic process known as diabetic retinopathy, or DR. Elevated blood glucose is the predominant risk factor for DR, so many people believe that glucose toxicity is the major contributor to the development of this disease. Yet, to date, no pharmaceuticals specifically targeting glucose-dependent pathways exist for DR.

Diabetes is a disease of broadly disordered metabolism that affects how cells handle lipids, amino acids and signaling networks that regulate growth and proliferation — in addition to its impact on glucose. Accordingly, abnormalities of lipid metabolism are common in diabetes. For example, patients with diabetes often suffer from nonalcoholic fatty liver disease, which is characterized by chronic positive energy balance causing increased lipid synthesis and elevated levels of hepatic triglycerides. Thus, we reasoned that the retina might switch its lipid metabolic programming in response to an abundance of fuel in diabetes.
To test this possibility, our group studied the pathways that govern retinal lipid biogenesis (the process of synthesizing fatty acids from small precursors) during experimental diabetes in mice. In multiple models of diabetes, we observed a roughly 70% increase over controls in the synthesis of retinal palmitate — a ubiquitous saturated fatty acid that forms a basic building block for many lipids. This shift in lipid production was likely due to elevated glucose alone, as isolated retinal tissue exposed to high glucose showed the same increase in palmitate production.

Mechanistically, high glucose levels increased enzymatic activity of two regulatory enzymes: acetyl Co-A carboxylase and fatty acid synthase, or FAS. Mice with partial FAS loss-of-function in rod photoreceptors — the predominant cell type of the retina — were spared from vision loss due to diabetes even though they developed severe systemic metabolic disease on par with control mice. Conversely, mice with FAS gain-of-function developed vision loss in half the time as wild-type mice after induction of diabetes. Taken together, our results implicate increased retinal FAS activity and elevated palmitate as root causes of vision loss in diabetes.
The mechanisms for palmitate toxicity in the retina remain elusive. Unlike in the liver, the diabetic retina does not develop intracellular lipid droplets and does not possess any significant triglyceride stores. Moreover, in comprehensive surveys of membrane lipids in the retina, we found only modest disease-associated changes. Instead, palmitate could elicit pathological signaling either through lipid second messengers or via lipidation of protein messengers. Our group is investigating these possibilities actively.
Our results shed some mechanistic light on a puzzling feature of human DR: Though glucose is the major risk factor for vision loss in diabetes, it only explains a fraction of the variability in disease progression. Differences among individuals in terms of their retinal lipid biosynthetic flux could account for some of the variance in glucose response.
Future pharmacotherapy to finely tune retinal lipid biogenesis in DR could offer a novel approach to the treatment of an increasingly common cause of visual disability.
Enjoy reading ASBMB Today?
Become a member to receive the print edition four times a year and the digital edition monthly.
Learn moreGet the latest from ASBMB Today
Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.
Latest in Science
Science highlights or most popular articles

How signals shape DNA via gene regulation
A new chromatin isolation technique reveals how signaling pathways reshape DNA-bound proteins, offering insight into potential targets for precision therapies. Read more about this recent MCP paper.

A game changer in cancer kinase target profiling
A new phosphonate-tagging method improves kinase inhibitor profiling, revealing off-target effects and paving the way for safer, more precise cancer therapies tailored to individual patients. Read more about this recent MCP paper.

How scientists identified a new neuromuscular disease
NIH researchers discover Morimoto–Ryu–Malicdan syndrome, after finding shared symptoms and RFC4 gene variants in nine patients, offering hope for faster diagnosis and future treatments.

Unraveling cancer’s spaghetti proteins
MOSAIC scholar Katie Dunleavy investigates how Aurora kinase A shields oncogene c-MYC from degradation, using cutting-edge techniques to uncover new strategies targeting “undruggable” molecules.

How HCMV hijacks host cells — and beyond
Ileana Cristea, an ASBMB Breakthroughs webinar speaker, presented her research on how viruses reprogram cell structure and metabolism to enhance infection and how these mechanisms might link viral infections to cancer and other diseases.

Understanding the lipid link to gene expression in the nucleus
Ray Blind, an ASBMB Breakthroughs speaker, presented his research on how lipids and sugars in the cell nucleus are involved in signaling and gene expression and how these pathways could be targeted to identify therapeutics for diseases like cancer.